1.
Discovering novel 3-nitroquinolines as a new class of anticancer agents
by LI, Hai-hong
Acta pharmacologica Sinica, 2008-12, Vol.29 (12), p.1529-1538
2.
Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and die...
by Feng, Li
Diabetologia, 2016-03-16, Vol.59 (6), p.1276-1286
3.
Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-[gamma] and PPAR-[alpha] agonists on carbohydrate and lipid metabolism in d...
by Li Feng
Diabetologia, 2016-06-01, Vol.59 (6), p.1276
4.
Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-I[superscript three] and PPAR-[alpha] agonists on carbohydrate and lipid me...
by Feng, Li
Diabetologia, 2016-06-01, Vol.59 (6), p.1276
5.
Discovering novel 3‐nitroquinolines as a new class of anticancer agents1
by LI, Hai‐hong
Acta pharmacologica Sinica, 2008-12, Vol.29 (12), p.1529-1538
6.
China Evolves from Imitation to Innovation
by Ming-Wei Wang
Drug Discovery & Development, 2005-06-01, Vol.8 (6), p.53
7.
Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET/CT
by Zheng, Shan
Annals of nuclear medicine, 2021-08-23, Vol.35 (12), p.1312-1320
8.
Characterization of the benign lesions with increased 68 Ga-FAPI-04 uptake in PET/CT
by Zheng, Shan
Annals of nuclear medicine, 2021-12, Vol.35 (12), p.1312
